Myeloproliferative neoplasms are rare blood cancers that develop when the bone marrow produces too many blood cells—red cells, white cells, or platelets—leading to various complications throughout the body.

Understanding Myeloproliferative Neoplasms

Myeloproliferative neoplasms, often abbreviated as MPNs, represent a group of rare blood cancers where the bone marrow—the soft, sponge-like tissue inside your bones—begins making too many blood cells. The word “myeloproliferative” describes how these conditions work: “myelo” refers to bone marrow, “proliferative” means rapid growth, and “neoplasm” indicates abnormal, uncontrolled cell growth. These diseases develop very slowly, which means many people may live with them for years before they notice any symptoms or problems.^[1]

Unlike many cancers that grow quickly and aggressively, MPNs are classified as chronic conditions. This means they are long-term diseases that progress gradually over time. The bone marrow in someone with an MPN doesn’t function properly because something has gone wrong with the instructions that control how blood cells are made and how many should be produced. While these conditions are serious and require medical attention, treatments are available that can ease symptoms and reduce the risk of MPNs developing into more serious diseases.^[1]

Epidemiology: Who Gets These Conditions

Myeloproliferative neoplasms are relatively uncommon in the general population. Each year, approximately 20,000 people are diagnosed with an MPN in the United States. Because these are rare diseases, many people have never heard of them before receiving their diagnosis, which can make the experience of being diagnosed particularly overwhelming and isolating.^[16]

Age is one of the most significant factors that influences who develops MPNs. These conditions most commonly affect people in their 50s, 60s, and older. While MPNs can occur in multiple age groups, including younger adults and even children in rare cases, the majority of diagnoses happen in middle-aged and elderly individuals. This age pattern means that many people who are diagnosed with MPNs are dealing with other health concerns related to aging at the same time.^[1]

Gender also plays a role in who develops certain types of MPNs. Polycythemia vera, which is the most common type of MPN, tends to occur more frequently in males. In contrast, essential thrombocythemia is more common in females. The remaining types of MPNs affect males and females in roughly equal numbers. Understanding these patterns helps doctors consider MPNs when patients present with certain symptoms and unusual blood test results.^[1]

Most people who develop MPNs are over 60 years old, though the disease can appear earlier in life. The conditions affect people across different racial and ethnic backgrounds, and while they are found worldwide, having detailed statistics on their occurrence in different populations remains challenging due to their rarity.^[8]

Causes: What Goes Wrong in the Bone Marrow

The exact cause of myeloproliferative neoplasms is not fully known, but researchers have made important discoveries about what happens inside the cells of people with these conditions. MPNs arise when precursor cells, also called blast cells, develop changes or errors in their genetic material. These cells are part of the myeloid lineage, which normally produces red blood cells, white blood cells, and platelets. When mutations occur in the genes of these cells, they begin to grow and multiply abnormally.^[3]

All blood cells start as stem cells in the bone marrow. These stem cells follow instructions from genes that tell them when to divide, when to stop dividing, and what type of blood cell to become. In a healthy person, the bone marrow carefully controls this process, making just the right number of each type of blood cell as the body needs them. However, when key genes develop mutations, they send new, incorrect instructions to the stem cells. These faulty instructions tell certain stem cells to keep dividing and multiplying without stopping, even when the body already has enough blood cells.^[1]

One of the most important genetic mutations found in MPNs involves a gene called JAK2. This gene makes a protein that acts like a switch, controlling blood cell production. In more than 95% of people with polycythemia vera and about 50% to 55% of those with essential thrombocythemia and primary myelofibrosis, researchers have found a specific change in the JAK2 gene known as the V617F mutation. This mutation causes the JAK2 protein to stay turned “on” all the time, leading to constant overproduction of blood cells.^[3]

Other genetic mutations have also been discovered in people with MPNs. Mutations in genes called CALR (calreticulin) and MPL (thrombopoietin receptor) have been identified in some patients. In essential thrombocythemia, the MPL mutation is found in up to 5% of cases. Different types of MPNs may have different genetic mutations driving the abnormal cell growth, which helps explain why the diseases affect blood cell production in various ways.^[3]

Genetics appears to play a central role in developing MPNs, but these genetic changes are almost always acquired during a person’s lifetime rather than inherited from parents. In other words, people are not typically born with the mutations that cause MPNs—these mutations develop later in life. However, in very rare instances, familial clusters of MPNs have been reported, where multiple family members develop these conditions, suggesting that in some cases there may be an inherited predisposition to developing the genetic mutations.^[6]

Risk Factors: What Increases Your Chances

Understanding the risk factors for myeloproliferative neoplasms can help identify who might be more likely to develop these conditions, though having risk factors does not guarantee someone will develop an MPN. The most significant predictor of developing an MPN is age. As mentioned earlier, these conditions predominantly affect people in their 50s, 60s, and beyond. The risk increases with each passing decade, making older age the strongest demographic risk factor for these diseases.^[1]

Biological sex influences risk for specific types of MPNs. Men have a higher likelihood of developing polycythemia vera compared to women, while women are more likely to be diagnosed with essential thrombocythemia. Understanding these patterns can help both patients and doctors recognize when symptoms or abnormal blood tests might warrant further investigation for an MPN.^[1]

Having a genetic mutation, particularly in the JAK2 gene, is strongly associated with a higher risk of developing an MPN. However, this mutation develops during a person’s lifetime rather than being inherited in most cases. Researchers believe that genetics play a central role not only in the development of MPNs but also in the risk of developing complications such as blood clots or bleeding problems. Some people may be more genetically susceptible to acquiring these mutations, though the mechanisms are still being studied.^[6]

Environmental exposures represent another category of risk factors. Exposure to high levels of ionizing radiation has been associated with an increased risk of developing myeloproliferative neoplasms. Similarly, exposure to certain chemicals, particularly benzene—a substance found in some industrial settings, tobacco smoke, and gasoline—has been linked to a higher risk of MPNs. People who work in industries where they might encounter these substances may face elevated risk, though most people with MPNs have no clear environmental exposure history.^[6]

In rare cases, having a family history of MPNs may increase risk. Although most cases occur sporadically without any family connection, there have been reports of familial clusters where multiple family members develop these conditions. This suggests that in some families, there may be an inherited tendency toward developing the genetic mutations that lead to MPNs, though this accounts for only a small fraction of all cases.^[6]

Symptoms: How MPNs Affect Daily Life

Many people with myeloproliferative neoplasms do not experience any symptoms when their disease is first detected. Instead, these conditions are often discovered during routine blood tests performed for other reasons. When a doctor sees unusual blood cell counts—too many red cells, white cells, or platelets—they may investigate further and eventually diagnose an MPN. This means that some people learn they have a blood cancer before they feel sick at all, which can be both surprising and anxiety-provoking.^[8]

When symptoms do occur, they can vary widely depending on which type of blood cell is overproduced and how the excess cells affect the body. One of the most common symptoms people report is severe tiredness or fatigue that doesn’t improve with rest. This exhaustion can interfere with daily activities, work, and quality of life. Many people with MPNs feel worn out even after a full night’s sleep, and the fatigue can be one of the most challenging aspects of living with these conditions.^[8]

Abnormal bleeding and bruising are common symptoms in some types of MPNs, particularly essential thrombocythemia where there are too many platelets. Although platelets normally help blood clot and stop bleeding, when there are too many of them, or when they don’t function properly, they can actually cause bleeding problems. People might notice that they bruise very easily from minor bumps, develop nosebleeds, or have bleeding gums. These bleeding issues occur because the excess platelets interfere with normal blood clotting.^[8]

On the other hand, too many blood cells can cause the blood to become thick and more likely to form clots. This creates a risk of serious complications like thrombosis—blood clots that can block blood vessels. Depending on where clots form, they can cause strokes, heart attacks, or clots in the legs or lungs. Some people with MPNs experience problems with their vision, such as blurred vision, because blood flow to the eyes is affected by thickened blood or tiny clots.^[10]

Other symptoms that people with MPNs may experience include frequent headaches, dizziness, ringing in the ears, night sweats that soak through clothing and bedding, and unintended weight loss. Many people report intense itching, especially after taking a warm bath or shower. This itching, called pruritus, can be particularly bothersome and difficult to relieve with standard anti-itch treatments. Some people also develop an enlarged spleen, which can cause discomfort or a feeling of fullness in the upper left part of the abdomen.^[8]

Getting infections more frequently than usual can also be a symptom, particularly if white blood cell production is affected. While white blood cells are part of the immune system and help fight infections, when the bone marrow produces too many abnormal white cells, they may not work properly, leaving the body more vulnerable to bacteria and viruses.^[8]

Prevention: Can MPNs Be Prevented

Unfortunately, because the exact cause of myeloproliferative neoplasms is not fully understood, and because the genetic mutations that lead to these conditions typically develop spontaneously during a person’s lifetime, there are no proven strategies to prevent MPNs from occurring. Unlike some diseases where specific lifestyle changes, vaccinations, or screening programs can significantly reduce risk, MPNs cannot currently be prevented through known interventions.^[6]

However, reducing exposure to known environmental risk factors may theoretically lower risk, even though the connection between these exposures and MPN development is not completely established. Avoiding unnecessary exposure to high levels of ionizing radiation and limiting contact with benzene and other toxic chemicals in occupational settings makes sense as a general health precaution, though it’s unclear how much this might reduce MPN risk specifically.^[6]

Since many MPNs are discovered during routine blood tests, maintaining regular healthcare visits and having blood work done as recommended by your doctor could lead to earlier detection. While this doesn’t prevent the disease, finding an MPN early—before symptoms develop or complications occur—allows for earlier treatment and monitoring, which can improve outcomes and quality of life.^[8]

For people who have already been diagnosed with an MPN, there are steps that can help prevent complications. Managing risk factors for blood clots is particularly important. This might include taking aspirin or other medications as prescribed, maintaining a healthy weight, staying physically active, managing blood pressure and cholesterol, and not smoking. These measures don’t prevent the MPN itself but can help reduce the risk of serious complications like heart attacks and strokes that are more common in people with these conditions.^[1]

Pathophysiology: What Happens Inside the Body

Understanding the pathophysiology of myeloproliferative neoplasms—the changes that occur in normal body functions—requires looking closely at how blood cells are normally made and what goes wrong in MPNs. In healthy individuals, hematopoietic stem cells in the bone marrow have the remarkable ability to renew themselves and create all the different types of blood cells the body needs. These stem cells can develop along two main pathways: the myeloid lineage and the lymphoid lineage.^[6]

The lymphoid lineage produces lymphocytes, a type of white blood cell important for fighting infections. The myeloid lineage produces three crucial types of mature blood cells: red blood cells that carry oxygen throughout the body, white blood cells (specifically granulocytes) that help fight infections and disease, and platelets that help blood clot to stop bleeding. This entire process of blood cell development is carefully controlled by the bone marrow environment, growth factors that signal when more cells are needed, and transcription factors that regulate gene activity.^[6]

In myeloproliferative neoplasms, genetic mutations disrupt this finely tuned system. The most commonly mutated gene, JAK2, produces a protein that functions as a tyrosine kinase—an enzyme that acts as an on-off switch for cell signaling. When the JAK2 gene has the V617F mutation, the switch gets stuck in the “on” position. This means cells receive continuous signals to grow and divide, even when the body doesn’t need more blood cells. The result is overproduction of one or more types of blood cells from the myeloid lineage.^[3]

As these abnormal stem cells divide and multiply, they eventually become mature blood cells that accumulate in the bone marrow and bloodstream. In polycythemia vera, for example, there are too many red blood cells, which causes the blood to become thicker than normal. This increased viscosity makes it harder for blood to flow smoothly through blood vessels, increasing the risk of clots forming. Thickened blood flows more slowly, which can lead to reduced oxygen delivery to tissues and organs, causing symptoms like headaches, dizziness, and fatigue.^[1]

In essential thrombocythemia, the bone marrow produces too many platelets. While platelets normally work together to form clots when you’re injured, having too many can paradoxically cause both clotting problems (because they can clump together inappropriately in blood vessels) and bleeding problems (because the excess platelets don’t function properly and interfere with normal clotting mechanisms). This explains why people with this condition may experience both types of symptoms.^[3]

Primary myelofibrosis involves additional pathological changes. In this condition, abnormal blood cells trigger a reaction that causes scar tissue, called fibrosis, to develop in the bone marrow. This scarring gradually replaces the normal spongy marrow with fibrous tissue, making it harder for the bone marrow to produce blood cells. As the bone marrow becomes less functional, the body attempts to compensate by making blood cells in other organs, particularly the spleen and liver. This process, called extramedullary hematopoiesis, can cause these organs to enlarge significantly, leading to abdominal discomfort and other symptoms.^[8]

The abnormal blood cells in MPNs may also behave differently from healthy cells in other ways. They might not mature properly, may have shorter or longer lifespans, or may not perform their normal functions effectively. For instance, white blood cells produced by the abnormal bone marrow may be less effective at fighting infections, even though there are more of them. This dysfunction explains why people with MPNs can experience both high blood cell counts and symptoms related to poor cell function.^[2]

Over time, the continuous overproduction of abnormal blood cells can lead to various complications throughout the body. The increased risk of blood clots can affect any organ system, potentially causing heart attacks, strokes, or clots in the lungs or legs. The enlarged spleen that occurs in many MPNs can cause discomfort and may trap and destroy blood cells, paradoxically leading to low blood counts despite the bone marrow’s overactivity. In some cases, MPNs can progress or transform into more aggressive blood cancers, such as acute myeloid leukemia, where immature blast cells accumulate rapidly. This transformation occurs in a minority of cases but represents a serious complication when it happens.^[2]